cathepsin

(redirected from Cathepsin S)
Also found in: Medical, Encyclopedia.
Related to Cathepsin S: Cathepsin L

ca·thep·sin

 (kə-thĕp′sĭn)
n.
Any of various enzymes found in animal tissue that catalyze the hydrolysis of proteins into smaller proteins.

[German Kathepsin, from Greek kathepsein, to digest : kat-, kata-, cata- + hepsein, to boil.]

cathepsin

(kəˈθɛpsɪn)
n
(Biochemistry) a proteolytic enzyme responsible for the autolysis of cells after death
[C20: from Greek kathepsein to boil down, soften]

ca•thep•sin

(kəˈθɛp sɪn)

n.
any of a class of intracellular enzymes that break down protein in certain abnormal conditions and after death.
[1925–30; < Greek kathéps(ein) to digest]
ca•thep′tic (-tɪk) adj.
References in periodicals archive ?
Cathepsins in Human Obesity: Changes in Energy Balance Predominantly Affect Cathepsin S in Adipose Tissue and in Circulation.
27) - Pipeline Review, H1 2016', provides in depth analysis on Cathepsin S (EC 3.
Cathepsin S level and activity in bronchoalveolar lavage fluid from COPD patients are higher than those from healthy volunteers [7].
ST), an emerging research-based pharmaceutical company, announced today the selection of its drug, MIV-247, as a candidate drug (CD) from its cathepsin S inhibitor project for the treatment of neuropathic pain.
The methods depend upon inhibiting invariant chain proteolysis by cathepsin S from class II MHC/invariant chain complexes, thereby reducing the competency of class II MHC molecules for binding antigenic peptides, reducing presentation of antigenic peptides by class II MHC molecules, and suppressing immune responses.
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that Schering AG has acquired its cathepsin S inhibitor small molecule drug program for the treatment of autoimmune diseases.
Medivir acquired all product rights to the Cathepsin S project.
STOCKHOLM, Sweden -- Medivir AB, a publicly traded pharmaceutical company based in Sweden and UK, has acquired all project rights for the development of Cathepsin S inhibitors from its former world-wide partner Peptimmune Inc.
The cathepsin S project, directed to autoimmune disorders, has recently developed compounds which are superior to the previously designated Candidate Drug, CD-1.
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced the initiation of Phase I clinical testing for its cathepsin S inhibitor, CRA-028129, for the treatment of psoriasis.
Celera Genomics (NYSE:CRA), an Applera Corporation business, today announced that the company had received an additional research milestone payment from Aventis Pharma, the pharmaceutical company of Aventis (NYSE:AVE), as part of the Cathepsin S inhibitor collaboration between the companies.
Medivir and Peptimmune, a business unit of Genzyme General, jointly announce today that, an orally active, small molecule inhibitor of the protease enzyme Cathepsin S, suppresses the development of arthritis in an animal disease model.